Skip to main content Back to Top
Advertisement

11/26/2019

Chlorothiazide Oral Tablets and Suspension

Products Affected - Description

    • Chlorothiazide oral tablet, Hikma, 500 mg, bottle, 100 count, NDC 00143-1210-01 - discontinued
    • Chlorothiazide oral tablet, Hikma, 500 mg, bottle, 1000 count, NDC 00143-1210-10 - discontinued
    • Chlorothiazide oral tablet, Mylan, 250 mg, bottle, 100 count, NDC 00378-0150-01 - discontinued
    • Chlorothiazide oral tablet, Mylan, 500 mg, bottle, 100 count, NDC 00378-0162-01 - discontinued

Reason for the Shortage

    • Mylan discontinued chlorothiazide tablets in September 2019.
    • Hikma discontinued chlorothiazide tablets.
    • Bausch health did not provide a reason for the shortage.

Available Products

    • Diuril oral suspension, Bausch Health, 250 mg / 5 mL 237 mL bottle, NDC 65649-0311-12

Estimated Resupply Dates

    • Bausch Health has Diuril suspension in 237 mL bottles available.

Updated

Updated November 26, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created November 4, 2019 by Rachael Freeman, PharmD, BCPS. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins